A novel approach to targeted immunotherapy, started nearly 2 decades ago, is now bearing fruit. The role of antibodies in the pathology of the MS plaque has been a hot area of basic research. Up until recently, MS was thought to be fundamentally a disease driven by the abnormal regulation of a type of immune cell called the T cell.
